Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2024-01-04 Report Publication Anno…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax calendrier de communication financière 2024
Report Publication Announcement Classification · 1% confidence The document is titled "Abivax calendrier de communication financière 2024" (Abivax 2024 financial communication calendar). It explicitly lists future dates for key corporate events, including the publication of annual results (associated with the Universal Registration Document 2024 and FORM 20-F), the Annual General Meeting (Assemblée Générale annuelle), and interim/quarterly results (associated with FORM 6-K). Since this document is an announcement detailing *when* other reports will be released, rather than being one of the reports itself (like the 10-K or IR), it fits the definition of a Report Publication Announcement (RPA). The document is short and serves to announce the schedule of future filings/events.
2024-01-04 French
Abivax 2024 Financial Communication Calendar
Report Publication Announcement Classification · 1% confidence The document is titled "Abivax 2024 Financial Communication Calendar" and was released on January 4, 2024. It explicitly lists future dates for various corporate reports, including the '2023 Annual Business and Financial Report (as of December 31, 2023) (Universal Registration Document 2024 and Annual Report on FORM 20-F)', the '2024 Half-Year Business and Financial Report', and the 'Third Quarter 2024 Financial Information'. Since the document itself is an announcement *about* when future reports will be released, and it is not the report itself, it fits the definition of a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because it is highly specific about future financial reporting schedules.
2024-01-04 English
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated December 21, 2023, from the French company ABIVAX, detailing the 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references compliance with French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This type of filing, which reports changes or updates to the total number of shares and voting rights, is a specific regulatory disclosure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit as it relates directly to the capital structure and share count, although it is a specific type of capital update. It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing (DIRS). Given the focus on the total number of shares and voting rights, SHA is the best classification.
2023-12-21 French
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.23.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated November 30, 2023, titled "Nombre d'actions composant le capital social et nombre total de droits de vote" (Number of shares comprising the share capital and total number of voting rights). It explicitly references French commercial code (article L. 233-8 II) and AMF regulations (article 223-16) for reporting voting rights and share counts as of a specific date (31/10/2023). This type of mandatory periodic disclosure regarding the total number of shares and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning capital structure and voting power. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the share count, although it is a periodic disclosure rather than a transaction announcement. However, given the nature of mandatory regulatory reporting on share capital structure, and the lack of a specific code for 'Share Capital/Voting Rights Disclosure', 'SHA' is the most appropriate classification as it relates directly to the capital structure components being reported. It is not a general regulatory filing (RNS) because it is highly specific to share capital.
2023-11-30 French
Abivax annonce la reprise de son contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is a press release from Abivax announcing the resumption of its liquidity contract ('contrat de liquidité') and the end of the stabilization period following a recent public offering. This type of announcement, which details financial arrangements related to share trading, capital structure management, or market stabilization activities, fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). While it relates to shares, it is specifically about the liquidity agreement rather than a general share issue (SHA) or buyback (POS). Given the context of managing market liquidity post-offering, CAP is the most appropriate classification.
2023-11-21 French
Abivax announces the resumption of its liquidity contract
Regulatory Filings Classification · 1% confidence The document is a short press release dated November 21, 2023, announcing the 'resumption of its liquidity contract' and the end of a stabilization period following an IPO. It details the shares and cash held for the contract. This type of announcement, which relates to market stabilization activities following a capital event (like an IPO mentioned in the context of the stabilization suspension), does not fit neatly into the primary financial reporting categories (10-K, IR, ER). It is a specific corporate action announcement. Since it is not a dividend notice (DIV), director dealing (DIRS), capital change (CAP), or a general report announcement (RPA), the most appropriate fallback category for a specific, non-standard regulatory/market announcement is 'Regulatory Filings' (RNS). The length is short, but the content is substantive news, not just a pointer to another document.
2023-11-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.